@ > @ > @ 1394 1397

(1)

و ﺖﺴﻴﺑ هرود ﻢﺘﻔﻫ

هرﺎﻤﺷ ، ﺖﺸﻫ ، نﺎﺑآ 1398 شﺮﻳﺬﭘ ﺦﻳرﺎﺗ

: 25 / 03 / 1398

ﻲﺳرﺮﺑ نارﺎﻤﻴﺑ ﻚﻳژﻮﻟﻮﻴﻣﺪﻴﭘا ﺖﻴﻌﺿو

يﺪﺒﻛ دﺎﺣ يرﺎﻤﻴﺑ ﻪﺑ ﻼﺘﺒﻣ

ﻪﻌﺟاﺮﻣ لﺎﺳ زا دﺰﻳ ﻲﻗوﺪﺻ ﺪﻴﻬﺷ نﺎﺘﺳرﺎﻤﻴﺑ ﻪﺑ هﺪﻨﻨﻛ

يﺎﻫ 1394 ﺎﺗ

1397

نﺎﻤﻠﺳ ﻦﺴﺣ ﻲﻨﻏور

*

نﺎﻴﻧﺎﺒﻏﺎﺑ دﻮﻤﺤﻣ ،1

،2

ﺪﻤﺤﻣ يرﺎﮔزور ﻦﺴﺣ

،3

ﻦﺴﺤﻣ آ يﺪﻧﻮﺧ يﺪﺒﻴﻣ

، 4

ﻲﮕﻴﺑﺮﻴﻣا ﻢﻇﺎﻛ 5

هﺎﺗﻮﻛ شراﺰﮔ

ﻪﻣﺪﻘﻣ : دﺎﺣ ﺖﻴﺗﺎﭙﻫ ﻻد

ﻞﻳ دراد ﻲﻔﻠﺘﺨﻣ .

نﻮﺧ لﺎﻘﺘﻧا ﺮﻴﻏ

هدﻮﻟآ ﺖﻴﺗﺎﭙﻫ لﺎﻘﺘﻧا عﻮﻴﺷ زا ،بﻮﻠﻄﻣﺎﻧ ﻲﻋﺎﻤﺘﺟا ﻂﺑاور زا ﺰﻴﻫﺮﭘ و سوﺮﻳو ﻪﺑ

وB

ﺖﺳا ﻪﺘﺳﺎﻛC

. ﻢﻫ يﺎﻫ ﺖﻴﺗﺎﭙﻫ عﻮﻴﺷ زا ﻢﻟﺎﺳ ياﺬﻏ و بآ ﻪﺑ ﻲﺳﺮﺘﺳد و يدﺎﺼﺘﻗا و ﻲﻋﺎﻤﺘﺟا ﻂﻳاﺮﺷ دﻮﺒﻬﺑ ﻦﻴﻨﭼ وE

ﻪﺘﺳﺎﻛA

ﺖﺳا ﻪﻠﺣﺮﻣ زا لﺎﻘﺘﻧا . Hyper Endimicity

ﻪﺑ ﻂﻳاﺮﺷ

Intermediate

ﺎﻳ و

low Endimicity

دﺎﺣ ﺖﻴﺗﺎﭙﻫ زوﺮﺑ ياﺮﺑ ار ﻪﻨﻴﻣز

A

ﻪﺑ ا رد صﻮﺼﺧ ﺖﺳا هدﺮﻛ ﻢﻫاﺮﻓ لﺎﺴﮔرﺰﺑ داﺮﻓ

. ﻦﻴﻴﻌﺗ ﻪﻌﻟﺎﻄﻣ ﻦﻳا زا فﺪﻫ يﺪﺒﻛ دﺎﺣ يرﺎﻤﻴﺑ ﻪﺑ ﻼﺘﺒﻣ نارﺎﻤﻴﺑ ﻚﻳژﻮﻟﻮﻴﻣﺪﻴﭘا ﺖﻴﻌﺿو

ﻪﻌﺟاﺮﻣ لﺎﺳ زا دﺰﻳ ﻲﻗوﺪﺻ ﺪﻴﻬﺷ نﺎﺘﺳرﺎﻤﻴﺑ ﻪﺑ هﺪﻨﻨﻛ يﺎﻫ

1394 ﺎﺗ 1397 ﻲﻣ ﺪﺷﺎﺑ .

ﻲﺳرﺮﺑ شور :

ﻲﻌﻄﻘﻣ ﻪﻌﻟﺎﻄﻣ ﻚﻳ ﻪﻌﻟﺎﻄﻣ ﻦﻳا -

ﻪﻌﺟاﺮﻣ نارﺎﻤﻴﺑ يور ﺮﺑ ﻪﻛ ﺖﺳا ﻲﻔﻴﺻﻮﺗ ﻪﻌﺟاﺮﻣ يﺪﺒﻛ دﺎﺣ ﻞﻜﺸﻣ ﺎﺑ هﺪﻨﻨﻛ

ﻪﺑ هﺪﻨﻨﻛ

ﻲﻗوﺪﺻ ﺪﻴﻬﺷ نﺎﺘﺳرﺎﻤﻴﺑ شراﻮﮔ ﻚﻴﻨﻴﻠﻛ لﺎﺳ زا

1394 لﺎﺳ ﺎﺗ 1397 ﺪﺷ مﺎﺠﻧا . ﻪﻧﻮﻤﻧ شور در زا ﺪﻌﺑ ﻪﻛ دﻮﺑ ترﻮﺻ ﻦﻳﺪﺑ يﺮﻴﮔ

ﻮﺳ ﻖﺒﻃ ﺮﺑ يﺪﺒﻛ ﻦﻣﺰﻣ يرﺎﻤﻴﺑ و ﻲﻜﺷﺰﭘ ﻖﺑا

تﺎﺸﻳﺎﻣزآ نارﺎﻤﻴﺑ

، ﻧارﺎﻤﻴﺑ ﻪﻛ ﻲ ﻲﻣ راﺮﻗ يﺪﺒﻛ دﺎﺣ يرﺎﻤﻴﺑ ﻪﺘﺳد رد ﺪﻨﺘﻓﺮﮔ

ﻪﻌﻟﺎﻄﻣ دراو

ﺪﻧﺪﺷ . ﻚﻳ ﺮﻫ عﻮﻴﺷ ﺪﺻرد نﺎﻴﺑ ياﺮﺑ ﺖﻴﺗﺎﭙﻫ عاﻮﻧا زا

مﺮﻧ زا دﺎﺣ يﺎﻫ راﺰﻓا

SPSS Inc., Chicago, IL; version 16

ﺪﻳدﺮﮔ هدﺎﻔﺘﺳا .

ﺞﻳﺎﺘﻧ : 23 ﻧﺪﺷ هداد ﺺﻴﺨﺸﺗ دﺎﺣ ﺖﻴﺗﺎﭙﻫ ﺎﺑ رﺎﻤﻴﺑ ﺪ

14 و دﺮﻣ رﺎﻤﻴﺑ 9

ﺪﻧدﻮﺑ نز رﺎﻤﻴﺑ .

رد ﺖﻴﺗﺎﭙﻫ ﻞﻣﺎﻋ 15

دﺎﺣ ﺖﻴﺗﺎﭙﻫ رﺎﻤﻴﺑ ،A

2

دﺎﺣ ﺖﻴﺗﺎﭙﻫ رﺎﻤﻴﺑ ،B

2 يﺪﺒﻛ نﻮﻤﻳاﻮﺗا ﺖﻴﺗﺎﭙﻫ رﺎﻤﻴﺑ و

4 دﻮﺑ ﻞﻠﻋ ﺮﻳﺎﺳ زا درﻮﻣ .

ﻪﺠﻴﺘﻧ يﺮﻴﮔ : 65 % رﺎﭼد ،ﻪﻌﻟﺎﻄﻣ ﻦﻳا رد ﺮﺿﺎﺣ نارﺎﻤﻴﺑ دﺎﺣ ﺖﻴﺗﺎﭙﻫ

ﺪﻧدﻮﺑ A

. ﻦﻳاﺮﺑﺎﻨﺑ دﺎﺣ ﺖﻴﺗﺎﭙﻫ ﻲﻜﻳA

ﻞﻣاﻮﻋ زا دﺎﺠﻳا رد ﻢﻬﻣ

ﻲﻣ ﺪﺒﻛ دﺎﺣ يرﺎﻤﻴﺑ ﺪﺷﺎﺑ

.

هژاو يﺪﻴﻠﻛ يﺎﻫ :

دﺎﺣ ﺖﻴﺗﺎﭙﻫ

، دﺎﺣ ﺖﻴﺗﺎﭙﻫ

، A

ﻲﺘﻴﺴﻴﻣﺪﻧا

عﺎﺟرا :

نﺎﻤﻠﺳ ﻲﻨﻏور نﺎﻴﻧﺎﺒﻏﺎﺑ ،ﻦﺴﺣ

،دﻮﻤﺤﻣ يرﺎﮔزور ﺪﻤﺤﻣ

،ﻦﺴﺣ يﺪﻧﻮﺧا يﺪﺒﻴﻣ ﻦﺴﺤﻣ

، ﻲﮕﻴﺑﺮﻴﻣا ﻢﻇﺎﻛ ﻼﺘﺒﻣ نارﺎﻤﻴﺑ ﻚﻳژﻮﻟﻮﻴﻣﺪﻴﭘا ﺖﻴﻌﺿو ﻲﺳرﺮﺑ.

ﻪﻌﺟاﺮﻣ يﺪﺒﻛ دﺎﺣ يرﺎﻤﻴﺑ ﻪﺑ لﺎﺳ زا دﺰﻳ ﻲﻗوﺪﺻ ﺪﻴﻬﺷ نﺎﺘﺳرﺎﻤﻴﺑ ﻪﺑ هﺪﻨﻨﻛ

يﺎﻫ 1394 ﺎﺗ 1397 . ﺪﻴﻬﺷ ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد ﻲﺸﻫوﮋﭘ ﻲﻤﻠﻋ ﻪﻠﺠﻣ

ﻲﻗوﺪﺻ دﺰﻳ 1398 ؛ 27 ) 8 :(

52 - 1846

.

1 - رﺎﻴﺸﻧاد , ﻲﻠﺧاد هوﺮﮔ ,

ﻲﻧﺎﻣرد ﻲﺘﺷاﺪﻬﺑ تﺎﻣﺪﺧ و ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد ﺪﺻ ﺪﻴﻬﺷ

،ﻲﻗو دﺰﻳ

، ناﺮﻳا ,

ﻲﻧﺎﻣرد ﻲﺘﺷاﺪﻬﺑ تﺎﻣﺪﺧ و ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد

،ﻲﻗوﺪﺻ ﺪﻴﻬﺷ دﺰﻳ

, ناﺮﻳا

3 - ﻦﻴﻐﻟﺎﺑ ﺪﺒﻛ شراﻮﮔ ﺺﺼﺨﺗ قﻮﻓ رﺎﻴﺘﺳد ,

ناﺮﻬﺗ ﻲﻧﺎﻣرد ﻲﺘﺷاﺪﻬﺑ تﺎﻣﺪﺧ و ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد ,

،ناﺮﻬﺗ ناﺮﻳا .

ﻣﺪﺧ و ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد دﺰﻳ ﻲﻧﺎﻣرد ﻲﺘﺷاﺪﻬﺑ تﺎ

دﺰﻳ ،ﻲﻗوﺪﺻ ﺪﻴﻬﺷ ,

ناﺮﻳا

5 - رﺎﻳدﺎﺘﺳا , ﻲﻠﺧاد هوﺮﮔ

، ﻲﻧﺎﻣرد ﻲﺘﺷاﺪﻬﺑ تﺎﻣﺪﺧ و ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد ،ﻲﻗوﺪﺻ ﺪﻴﻬﺷ

دﺰﻳ , ناﺮﻳا .

)*

لﻮﺌﺴﻣ هﺪﻨﺴﻳﻮﻧ (؛

ﻦﻔﻠﺗ : 09131512000 ﻲﻜﻴﻧوﺮﺘﻜﻟا ﺖﺴﭘ ،

: [email protected]

، ﻲﺘﺴﭘ قوﺪﻨﺻ :

8916888134

(2)

ﻪﻣﺪﻘﻣ

ﻠﻣﺎﻋ دﺎﺣ ﺖﻴﺗﺎﭙﻫ ﻲ

ﻢﻬﻣ رد ﻲﻣ ﺎﻴﻧد رد ﺮﻴﻣ و گﺮﻣ ﺪﺷﺎﺑ

يﺎﻫرﻮﺸﻛ رد ﺎﻣا ﻪﺘﻓﺎﻳ ﺶﻫﺎﻛ ﻪﺘﻓﺮﺸﻴﭘ يﺎﻫرﻮﺸﻛ رد نآ عﻮﻴﺷ ﺎﻳ ﻪﻌﺳﻮﺗ ﺮﺘﻤﻛ ﻲﻳﺎﻘﻳﺮﻓآ ﻪﺘﻓ

، آ ﻪﺑ ﺎﻴﺳآ و ﻲﺑﻮﻨﺟ يﺎﻜﻳﺮﻣ صﻮﺼﺧ

ﻧﺎﻴﻣروﺎﺧ ﺖﺳا ﻻﺎﺑ ﻪ .

ﻲﺳوﺮﻳو ﺖﻴﺗﺎﭙﻫ ﺎﻜﻳﺮﻣآ رد و A

و B C

ﻞﻣﺎﻋ 97 % زا دراﻮﻣ ﻲﻣ دﺎﺣ ﺖﻴﺗﺎﭙﻫ ﺪﺷﺎﺑ

) 1 .(

نﻮﻴﺳﺎﻨﻴﺴﻛاو

ﺖﻴﺗﺎﭙﻫ ﻪﻴﻠﻋ ﺳ زا B

لﺎ 1372 نﻮﺧ لﺎﻘﺘﻧا و ﺎﻣ رﻮﺸﻛ رد يﺎﻫ

لاﺮﻳو ﺖﻴﺗﺎﭙﻫ لﺎﻘﺘﻧا دراﻮﻣ زا ﻢﻟﺎﺳ و B

ﺖﺳا ﻪﺘﺳﺎﻛ C

) 2 (

و بآ ﻊﺑﺎﻨﻣ ﻪﺑ ﻲﺳﺮﺘﺳد و يدﺎﺼﺘﻗا و ﻲﻋﺎﻤﺘﺟا ﻂﻳاﺮﺷ دﻮﺒﻬﺑ زا ﻢﻟﺎﺳ ياﺬﻏ ﺖﻴﺗﺎﭙﻫ لﺎﻘﺘﻧا عﻮﻴﺷ

ﻖﻳﺮﻃ زا هﺪﻧﻮﺷ ﻞﻘﺘﻨﻣ يﺎﻫ

ﺖﻴﺗﺎﭙﻫ ﺮﻴﻈﻧ اﺬﻏ و بآ و A

ﺖﺳا ﻪﺘﺳﺎﻛ E

) 3،4 ( ﺎﺑ ﻦﻜﻴﻟو

ﻳاﺮﺷ دﻮﺒﻬﺑ ﺎﻴﻧد يدﺎﺼﺘﻗا و ﻲﻋﺎﻤﺘﺟا ﻂ

) 5 ( ﻪﺑ و ناﺮﻳا رد هﮋﻳو

ﻪﺑ ﺼﻣ ﻂﻳاﺮﺷ لﺎﻘﺘﻧا و دﺰﻳ ﺮﻬﺷ رد صﻮﺼﺧ ﺖﻴﺗﺎﭙﻫ ﻪﻴﻠﻋ ﺖﻴﻧﻮ

ﻪﻘﻄﻨﻣ زاA

ﻻﺎﺑ عﻮﻴﺷ ﺎﺑ

Hyper Endimicity)

( ﻪﻘﻄﻨﻣ ﻪﺑ ﺎﺑ

ﻂﺳﻮﺘﻣ عﻮﻴﺷ

(IntermediateEndimicity)

ﺎﻳ و ﻦﻴﻳﺎﭘ عﻮﻴﺷ

(low Endimicity)

ﺖﻴﺗﺎﭙﻫ ﻪﺑ ﻼﺘﺑا ضﺮﻌﻣ رد ار ناﻮﺟ داﺮﻓا ،

A

ﺎﺑ تاﺮﻫﺎﻈﺗ ﺪﻳﺪﺷ ﻲﻨﻴﻟﺎﺑ

ﺮﺗ ﺖﺳا هداد راﺮﻗ .

رد ﻲﺳرﺮﺑ ﻚﻳ رد

ﺖﻴﻧﻮﺼﻣ ناﺰﻴﻣ دﺰﻳ ﺮﻬﺷ لﺎﺳ رد

1370 ﺶﻧاد رد ﻊﻄﻘﻣ نازﻮﻣآ

ﻲﺋﺎﻤﻨﻫار 1

/ 92 % ﺖﺳا هدﻮﺑ )

6 (.

ﺳرﺮﺑ رد لﺎﺳ ﻲ 1389 ناﺰﻴﻣ

ﺶﻧاد رد ﺖﻴﻧﻮﺼﻣ ﻣ ﻦﻳا نازﻮﻣآ

ﺎﻬﻨﺗ ﻊﻄﻘ 8

/ 17 % ﺖﺳا هدﻮﺑ

) ﻪﺘﻓﺎﻳ هﺪﺸﻧ پﺎﭼ يﺎﻫ ) (

7 ( ﻪﻌﻟﺎﻄﻣ زﻮﻨﻫ ﻦﻳا ﺐﻗاﻮﻋ يور ﺮﺑ يا

ﺖﻴﺗﺎﭙﻫ ﻞﺑﺎﻘﻣ رد ﺖﻴﻧﻮﺼﻣ ﺮﻴﻴﻐﺗ هﺪﺸﻧ مﺎﺠﻧا A

. فﺪﻫ ﻪﻌﻟﺎﻄﻣ

ﻦﻴﻴﻌﺗﺮﻴﺧا دﺎﺣ يرﺎﻤﻴﺑ ﻪﺑ ﻼﺘﺒﻣ نارﺎﻤﻴﺑ ﻚﻳژﻮﻟﻮﻴﻣﺪﻴﭘا ﺖﻴﻌﺿو

ﻪﻌﺟاﺮﻣ يﺪﺒﻛ زا دﺰﻳ ﻲﻗوﺪﺻ ﺪﻴﻬﺷ نﺎﺘﺳرﺎﻤﻴﺑ ﻪﺑ هﺪﻨﻨﻛ

لﺎﺳ يﺎﻫ 1394 ﺎﺗ 1397 ﻲﻣ ﺪﺷﺎﺑ . ﻲﺳرﺮﺑ شور

لﺎﺳ ﻦﻳدوﺮﻓ زا 1394

هﺎﻣ يد ﺎﺗ 1397

ﻞﻜﺸﻣ ﺎﺑ نارﺎﻤﻴﺑ

ﻪﻌﺟاﺮﻣ يﺪﺒﻛ ﺪﺒﻛ و ﻲﺷراﻮﮔ يرﺎﻤﻴﺑ ﻚﻴﻨﻴﻠﻛ ﻪﺑ هﺪﻨﻨﻛ

ﻲﻗوﺪﺻ ﺪﻴﻬﺷ نﺎﺘﺳرﺎﻤﻴﺑ ﺪﻨﺘﻓﺮﮔ راﺮﻗ ﻲﺳرﺮﺑ درﻮﻣ

. شور

ﻪﻧﻮﻤﻧ يﺪﺒﻛ ﻦﻣﺰﻣ يرﺎﻤﻴﺑ در زا ﺪﻌﺑ ﻪﻛ دﻮﺑ ترﻮﺻ ﻦﻳﺪﺑ يﺮﻴﮔ

و ﻲﻜﺷﺰﭘ ﻖﺑاﻮﺳ ﻖﺒﻃ ﺮﺑ تﺎﺸﻳﺎﻣزآ

نارﺎﻤﻴﺑ , ﻧارﺎﻤﻴﺑ ﻪﻛ ﻲ رد

ﻲﻣ راﺮﻗ يﺪﺒﻛ دﺎﺣ يرﺎﻤﻴﺑ ﻪﺘﺳد ﺪﻨﺘﻓﺮﮔ

ﺪﻧﺪﺷ ﻪﻌﻟﺎﻄﻣ دراو ، .

داﺪﻌﺗ 97 ﺪﻧدﻮﻤﻧ ﻪﻌﺟاﺮﻣ يﺪﺒﻛ ﻞﻜﺸﻣ ﺎﺑ رﺎﻤﻴﺑ .

ﺶﻳاﺰﻓا ﻢﻳﺰﻧآ

ﺪﺒﻛ يﺎﻫ

Alanin Amino Transfrase (ALT)

و

Aspartate AminoTransfrase (AST)

زا ﺶﻴﺑ 1 / 8 ﺎﺗ 10 ﺮﺑاﺮﺑ

ﻪﺘﻓﺎﻳ ﭻﻴﻫ ندﻮﺒﻧ و ،ﻲﺒﻠﻗ يﺪﺒﻛ ﻞﻜﺸﻣ ﻪﻘﺑﺎﺳ نوﺪﺑ ،لﺎﻣﺮﻧ ﻦﻣﺰﻣ يرﺎﻤﻴﺑ دﻮﺟو ﺮﺑ ﻲﻨﺒﻣ ﻲﻓاﺮﮔﻮﻧﻮﺳ و ﻲﻨﻴﻟﺎﺑ ،ﻲﻫﺎﮕﺸﻳﺎﻣزآ ﻪﺑ ،يﺪﺒﻛ ﺪﺷ ﻪﺘﻓﺮﮔ ﺮﻈﻧ رد ﺪﺒﻛ يرﺎﻤﻴﺑ ندﻮﺑ دﺎﺣ ناﻮﻨﻋ

. رد

رﺎﻤﻴﺑ ﺎﻫﺮﻛرﺎﻣ لاﺮﻳو ،يﺪﺒﻛ دﺎﺣ يرﺎﻤﻴﺑ ﻮﻠﺑﺎﺗ ﺎﺑ نا

ﻞﻣﺎﺷ

IgMAb,AntiHBCIgM-Ab, Anti HAV-HCVAb

ﺮﻴﻈﻧ نﻮﻤﻳاﻮﺗا يﺎﻫﺮﻛرﺎﻣ ﻲﺘﻧآ

ﻛﻮﻧ ﻠ زﺎﺌ ﻲﺘﻧآ يدﺎﺑ ) ،(ANA

ﻲﺘﻧآ يدﺎﺑ فﺎﺻ ﻪﭽﻴﻫﺎﻣ لﻮﻠﺳ ﻪﻴﻠﻋ )

Anti-smoothmuscle Ab

( ،

وﺮﺳ ﻲﻣﺮﺳ ﺢﻄﺳ و ﻟ

ﺳﻼﭘﻮ ﻤ راردا ﺲﻣ و ﻦﻴ 24

ﺲﻣ و ﻪﺘﻋﺎﺳ

ﺎﺳﺎﻨﺷ ياﺮﺑ مﺮﺳ نﻮﺴﻠﻳو يرﺎﻤﻴﺑ ﻪﺑ نﺎﻳﻼﺘﺒﻣ ﻲﻳ

ﻲﺳرﺮﺑ دﺎﺣ

ﺪﻳدﺮﮔ . ﻲﻠﻴﺑ ﻲﻧﻮﺧ ﺢﻄﺳ نﺎﻣز ،لﺎﺗﻮﺗ ﻦﻴﺑور

ﻦﻴﺒﻣوﺮﺗوﺮﭘ

INR

,(PT)

ﺖﻓﺮﺸﻴﭘ ضﺮﻌﻣ رد داﺮﻓا ﻲﻳﺎﺳﺎﻨﺷ ياﺮﺑ نﻮﺧ ﺪﻨﻗ ﺢﻄﺳ و ﺪﻳدﺮﮔ ﻲﺳرﺮﺑ ﺪﺒﻛ دﺎﺣ ﻲﻳﺎﺳرﺎﻧ و يﺪﺒﻛ دﺎﺣ زوﺮﻜﻧ ﺖﻤﺳ ﻪﺑ .

ﺶﻳاﺰﻓا ﺎﺑ داﺮﻓا و AST

ﻴﺑ ALT

زا ﺶ 1 / 8 ﺎﺗ 10 ﺮﺑاﺮﺑ لﺎﻣﺮﻧ ،

،يﺪﺒﻛ ﻦﻣﺰﻣ يرﺎﻤﻴﺑ زا ﻲﺘﻣﻼﻋ دﻮﺟو نوﺪﺑ ﻦﺘﺷاﺪﻧ

ﻪﻘﺑﺎﺳ

ندﻮﺑ ﺖﺒﺜﻣ و يﺪﺒﻛ ﻲﻠﺒﻗ يرﺎﻤﻴﺑ

Anti HAV IgMAb

ﻪﺑ ناﻮﻨﻋ

ﺖﻴﺗﺎﭙﻫ ﺮﺛا رد ﺪﺒﻛ دﺎﺣ ﺮﻫﺎﻈﺗ ﺎﺑ يرﺎﻤﻴﺑ ﺪﻧﺪﺷ ﻪﺘﻓﺮﮔ ﺮﻈﻧ ردA

ترﻮﺻ ﻪﺑ ﻲﺗﺎﭘﻮﻟﺎﻔﺴﻧا دﻮﺟو نﺎﻬﻨﭘ

(covert)

ﺎﻳ آ رﺎﻜﺷ

(overt)

ﺎﻳ و

نﺎﻣز ﺶﻳاﺰﻓا ﻪﺑ INR

زا ﺶﻴﺑ 5 / 1 و ﻳ يوﺎﺴﻣ ﺎ 5

/ 1 يﺮﺘﺴﺑ ﻞﻴﻟد

دﻮﺑ نارﺎﻤﻴﺑ ندﻮﻤﻧ .

ﺖﺴﺗ ﺮﻫ يﺮﺘﺴﺑ نارﺎﻤﻴﺑ رد يﺪﺒﻛ يﺎﻫ 48

ﺮﻴﻏ نارﺎﻤﻴﺑ رد و رﺎﺑ ﻚﻳ ﺖﻋﺎﺳ ﺮﻫ يﺮﺘﺴﺑ

4 ﺗ رﺎﺑ ﻚﻳ زور رﻮﺒﻋ ﺎ

ﻲﻣ راﺮﻜﺗ ﻲﻧاﺮﺤﺑ ﻪﻠﺣﺮﻣ زا ﺪﺷ

.

يرﺎﻣآ ﻞﻴﻠﺤﺗ و ﻪﻳﺰﺠﺗ

عﻮﻧ زا ﻪﻌﻟﺎﻄﻣ ﻲﻌﻄﻘﻣ

و هدﻮﺑ ﻲﻔﻴﺻﻮﺗ مﺮﻧ زا

راﺰﻓا

SPSS

Inc., Chicago, IL; version 16

ﻚﻳ ﺮﻫ عﻮﻴﺷ ﺪﺻرد نﺎﻴﺑ ياﺮﺑ

ﺪﺷ هدﺎﻔﺘﺳا دﺎﺣ ﺖﻴﺗﺎﭙﻫ عاﻮﻧا زا .

ﻲﻗﻼﺧا تﺎﻈﺣﻼﻣ

هﺎﮕﺸﻧاد ﻂﺳﻮﺗ ﻖﻴﻘﺤﺗ ﻦﻳا لازﻮﭘوﺮﭘ .

ﻲﻜﺷﺰﭘ مﻮﻠﻋ تﺎﻣﺪﺧ و

ﻲﻧﺎﻣرد ﻲﺘﺷاﺪﻬﺑ ﻲﻗوﺪﺻ ﺪﻴﻬﺷ

دﺰﻳ ﺖﺳا هﺪﺷ ﺪﻴﻳﺎﺗ .

ﺞﻳﺎﺘﻧ

زا عﻮﻤﺠﻣ 97 يﺪﺒﻛ ﻞﻜﺸﻣ ﺎﺑ رﺎﻤﻴﺑ ﻪﻛ

ﺪﻧﺪﺷ ﻲﺳرﺮﺑ 23

ﻣ ﻪﺑ دورو ﻂﻳاﺮﺷ رﺎﻤﻴﺑ ﻌﻟﺎﻄ

ﻪ ار ﺪﻨﺘﺷاد . 14 و دﺮﻣ رﺎﻤﻴﺑ 9

رﺎﻤﻴﺑ

(3)

دﺰﻳ ﻲﻗوﺪﺻ ﺪﻴﻬﺷ ﻲﻧﺎﻣرد ـ ﻲﺘﺷاﺪﻬﺑ تﺎﻣﺪﺧ و ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد ﻪﻠﺠﻣ

هرﺎﻤﺷ ، ﻢﺘﺸﻫ ، نﺎﺑآ 1398

ﺪﻧدﻮﺑ نز . نارﺎﻤﻴﺑ ﻲﻨﺳ ﻂﺳﻮﺘﻣ 21

لﺎﺳ دﻮﺑ . 16 رﺎﻤﻴﺑ ﻲﻣﻮﺑ

و دﺰﻳ 2 رﺎﻤﻴﺑ ﺮﻴﻏ ﻲﻧاﺮﻳا و 5 رﺎﻤﻴﺑ ﺮﻴﻏ دﺰﻳ ﻲﻣﻮﺑ ﺪﻧدﻮﺑ

. زا 23

رﺎﻤﻴﺑ دﺎﺣ ﺖﻴﺗﺎﭙﻫ ﻪﺑ ﻼﺘﺒﻣ

، 15 دﺎﺣ ﺖﻴﺗﺎﭙﻫ رﺎﻤﻴﺑ ،A

2 رﺎﻤﻴﺑ

دﺎﺣ ﺖﻴﺗﺎﭙﻫ ،B

2 ﻤﻴﺑ ﻚﻳ و يوراد ﺖﻴﺗﺎﭙﻫ رﺎﻤﻴﺑ دﺎﺣ ﺖﻴﺗﺎﭙﻫ رﺎ

ا ﻠﻜﻟ ﺪﻨﺘﺷاد ﻲ .

ود رﺎﻤﻴﺑ ﻮﺗا ﺖﻴﺗﺎﭙﻫ ﻳا

ﻴﻤ ﻪﺑ ﻼﺘﺒﻣ رﺎﻤﻴﺑ ﻚﻳ و نﻮ

دﺎﺣ نﻮﺴﻠﻳو يرﺎﻤﻴﺑ دﻮﺑ

) ﻚﻳ لوﺪﺟ (

نارﺎﻤﻴﺑ زا ﻪﺑ ﻼﺘﺒﻣ

دﺎﺣ ﺖﻴﺗﺎﭙﻫ ,A

5 رﺎﻤﻴﺑ ترﻮﺻ ﻪﺑ ﺪﻧﺪﺷ يﺮﻴﮕﻴﭘ ﻲﻳﺎﭘﺮﺳ

. 10

ﻪﺑ رﺎﻤﻴﺑ ﻣز و ﺪﻳﺪﺷ غاﺮﻔﺘﺳا و عﻮﻬﺗ ﻞﻴﻟد نﺎ

ﺎﻳ يوﺎﺴﻣ INR

يﻻﺎﺑ 1 ﺷ شرﺎﺧ و يدرز و ﺪﻧﺪﺷ يﺮﺘﺴﺑ نﺎﺘﺳرﺎﻤﻴﺑ رد ﺪﻳﺪ

. زا

نﺎﺘﺳرﺎﻤﻴﺑ رد يﺮﺘﺴﺑ نارﺎﻤﻴﺑ ﺪﻨﻣزﺎﻴﻧ رﺎﻤﻴﺑ ﺞﻨﭘ

ﻦﺘﻓﺮﮔ راﺮﻗ رد

ﻪﺑ ﺪﺒﻛ ﺪﻧﻮﻴﭘ يﺪﻨﻤﻧاﻮﺗ ياراد ﺰﻛﺮﻣ ﻪﺑ لﺎﻘﺘﻧا ﺖﺴﻴﻟ ﻞﻴﻟد

ﺪﻧﺪﺷ ﺪﺒﻛ دﺎﺣ ﻲﺋﺎﺳرﺎﻧ ﺖﻤﺳ ﻪﺑ ﺖﻓﺮﺸﻴﭘ لﺎﻤﺘﺣا .

لوﺪﺟ 1 : عﻮﻴﺷ ا ﻮﻧ ا ﺖﻴﺗﺎﭙﻫ ع ﺎﻫ ﻲﺳرﺮﻳ درﻮﻣ نارﺎﻤﻴﺑ رد دﺎﺣ ي

ﺖﻴﺗﺎﭙﻫ عﻮﻧ نﻮﺴﻠﻳو

ﺖﻴﺗﺎﭙﻫ ﻲﻳوراد ﺖﻴﺗﺎﭙﻫ

ﻲﻠﻜﻟا ﺖﻴﺗﺎﭙﻫ نﻮﻴﻤﻳاﻮﺗا ﺖﻴﺗﺎﭙﻫ B

) دﺎﺣ ( ﺖﻴﺗﺎﭙﻫ A

) دﺎﺣ (

داﺪﻌﺗ 1

2

1

2

15

ﺪﺻرد 4

/ 4 7 / 8 4 / 4 7 / 8 7

/ 8 1

/ 65

ﺚﺤﺑ

ﻪﻧﻻﺎﺳ ﻲﻧﺎﻬﺟ ﺖﺷاﺪﻬﺑ رﺎﻣآ سﺎﺳاﺮﺑ 4

/ 1 نﻮﻴﻠﻴﻣ ﺮﻔﻧ ﺎﻴﻧد رد

ﺖﻴﺗﺎﭙﻫ ﺎﺑ ﺪﻧﻮﺷ ﻲﻣ هدﻮﻟآ A

. و ﻲﻋﺎﻤﺘﺟا ﻂﻳاﺮﺷ دﻮﺒﻬﺑ ﺎﺑ

ﺮﺘﻬﺑ ﻲﺳﺮﺘﺳد ﺑﺎﻨﻣ ﻪﺑ

يرﺎﻤﻴﺑ عﻮﻴﺷ زا ﻢﻟﺎﺳ ياﺬﻏ و بآ ﻊ ﻲﻳﺎﻫ

ﻛ ﻲﻣ لﺎﻘﺘﻧا ﻊﺒﻨﻣ ود ﻦﻳا ﻖﻳﺮﻃ زا ﻪ ﻈﻧ ،ﺪﻨﺑﺎﻳ

ﻴ ﺖﻴﺗﺎﭙﻫ ﺮ

A

ﺖﻴﺗﺎﭙﻫ ﻴﭘﺮﺘﻛﺎﺑﻮﻜﻴﻠﻫ ﺖﻧﻮﻔﻋ وE

ﻲﻣ ﻪﺘﺳﺎﻛ ،يرﻮﻠ يرﺎﺘﻓﺮﮔ دﻮﺷ

ﺖﻴﺗﺎﭙﻫ ﺎﺑ ﺮﻳز ﻦﻴﻨﺳ ردA

10 ﻪﺑ و لﺎﺳ لﺎﺳ ﺶﺷ ﺮﻳز صﻮﺼﺧ

نوﺪﺑ ﺐﻠﻏا گﺮﻣ و ﺖﺳا ﺖﻣﻼﻋ

و ردﺎﻧ رﺎﻴﺴﺑ ﺮﻴﻣ ﻲﻣ

ﺪﺷﺎﺑ ) 8 (.

ﻲﻣ نﺎﺸﻧ ﻪﻌﻟﺎﻄﻣ ﻦﻳا ﺞﻳﺎﺘﻧ ﻪﻛ ﺪﻫد

زا ﺶﻴﺑ زا ﻲﻤﻴﻧ ﺮﻫﺎﻈﺗ دراﻮﻣ

ﺖﻴﺗﺎﭙﻫ ﻞﻴﻟد ﻪﺑ ﻲﻧاﻮﺟ ﻦﻴﻨﺳ رد دﺎﺣ يﺪﺒﻛ ﺪﺷﺎﺒﻴﻣ A

.

دﺎﺣ ﺖﻴﺗﺎﭙﻫ ﺶﻳاﺪﻴﭘ ضراﻮﻋ ﺎﺑ ﺮﻤﻋ يﻻﺎﺑ ﻦﻴﻨﺳ رد A

ﺪﻳﺪﺷ يﺮﺗ ﻲﻣ هاﺮﻤﻫ دﻮﺷ

. ﻲﻣ اﺪﻴﭘ ﺪﻳﺪﺷ ﻲﻨﻴﻟﺎﺑ تاﺮﻫﺎﻈﺗ و ﺪﻨﻛ

.

ﻦﺳ زا ﺪﻌﺑ 40

ناﺰﻴﻣ ﻲﮕﻟﺎﺳ ﺣ ﻪﺑ ﺮﻴﻣ و گﺮﻣ

دوﺪ 2 % ﺶﻳاﺰﻓا

ﻲﻣ ﻲﻟﺎﺣ رد ﺪﺑﺎﻳ ﻪﭽﺑ رد ناﺰﻴﻣ ﻦﻳا ﻪﻛ

زا ﺮﺘﻤﻛ ﺎﻫ 1

/ 0 % ﻲﻣ ﺪﺷﺎﺑ

) 9،10،11 (.

ﺖﻴﺗﺎﭙﻫ ﺎﺑ يرﺎﺘﻓﺮﮔ ﺪﻳﺪﺷ دراﻮﻣ زا يدﺎﻳز تﺎﺷراﺰﮔ ﻻﺎﺑ ﻦﻴﻨﺳ رد A

دﻮﺟو يﺰﻐﻣ يﺮﻴﮔرد ﺮﻴﻈﻧ دراد

) 12 ( رد

ﻪﻌﻟﺎﻄﻣ ا يور ﺮﺑ نارﺎﻜﻤﻫ و ﻲﻨﻴﻌﻣ ﻂﺳﻮﺗ ﻪﻛ يا ﺗ

ﻴ نارﺎﻤﻴﺑ يژﻮﻟﻮ

ﻲﺋﺎﺳرﺎﻧ تاﺮﻫﺎﻈﺗ ﺎﺑ يﺪﺒﻛ دﺎﺣ

ﻪﻛ ﺪﺒﻛ ﺪﻧﻮﻴﭘ ﺰﻛﺮﻣ ﻪﺑ

ﺪﻧدﻮﺑ هﺪﺷ هداد لﺎﻘﺘﻧا زاﺮﻴﺷ يزﺎﻤﻧ نﺎﺘﺳرﺎﻤﻴﺑ

، ﺪﺷ مﺎﺠﻧا داﺪﻌﺗ

45 يﺎﻫ لﺎﺳ رد رﺎﻤﻴﺑ 1394

و 1395 ﺪﻧﺪﺷ ﻲﺳرﺮﺑ .

ﻦﻳا ﺞﻳﺎﺘﻧ

ﻳﺎﺷ ﻪﻛ داد نﺎﺸﻧ ﻪﻌﻟﺎﻄﻣ ﻊ

يﺪﺒﻛ دﺎﺣ ﻲﺋﺎﺳرﺎﻧ ﺖﻠﻋ ﻦﻳﺮﺗ ﻞﺑﺎﻗ

دﺎﺣ ﺖﻴﺗﺎﭙﻫ نارﺎﻤﻴﺑ ﻦﻳا رد ﺺﻴﺨﺸﺗ ﺖﻴﻣﻮﻤﺴﻣ نآ زا ﺪﻌﺑ وA

اد و ﻲﺋور ﻲﻣ نﻮﻤﻳاﻮﺗا ﺖﻴﺗﺎﭙﻫ يﺪﻌﺑ ﻪﻠﻫو رد ﺪﺷﺎﺑ

. ﺮﺑ ﻪﻌﻟﺎﻄﻣ ﻦﻳا

ﻪﭼﺮﮔا و هﺪﺷ مﺎﺠﻧا لﺎﻔﻃا و ﻎﻟﺎﺑ ﺖﻴﻌﻤﺟ يور ﻲﻨﺳ ﻂﺳﻮﺘﻣ

نارﺎﻤﻴﺑ 8 /

±12 4 / 29 ﺖﺳا هﺪﺷ شراﺰﮔ .

دراﻮﻣ ﻲﻣﺎﻤﺗ ﺎﺒﻳﺮﻘﺗ ﺎﻣا

ﺖﺳا هدﺎﺘﻓا قﺎﻔﺗا ﻎﻟﺎﺑ داﺮﻓا رد گﺮﻣ ﺎﻳ و ﺪﺒﻛ ﺪﻧﻮﻴﭘ ﻪﺑ ﺮﺠﻨﻣ ) 13 .(

ﻲﺳرﺮﺑ ﺞﻳﺎﺘﻧ ا رد ﻒﻠﺘﺨﻣ يﺎﻫ

ﺖﻴﻧﻮﺼﻣ ناﺰﻴﻣ ﺎﺑ طﺎﺒﺗر رد

ﻲﻣ نﺎﺸﻧ ار ﻲﻔﻠﺘﺨﻣ ﺞﻳﺎﺘﻧ رﻮﺸﻛ ﺪﻫد

. رد هﺪﺷ مﺎﺠﻧا تﺎﻌﻟﺎﻄﻣ

لﺎﺳ رد نﺎﻬﻔﺻا 1388

لﺎﺳ رد ناﺮﻬﺗ رد و 1384

ندﻮﺑ ﻦﻴﻳﺎﭘ زا

دراد ﺖﻳﺎﻜﺣ ﺖﻴﻧﻮﺼﻣ ناﺰﻴﻣ )

14 (.

ﻚﻳ رد

Systematic review

خﺮﻓ ﻂﺳﻮﺗ لﺎﺳ رد نارﺎﻜﻤﻫ و نﺎﮔداز

1394 رﻮﺸﻛ ﻪﻛ داد نﺎﺸﻧ

ﺎﺑ ار ناﺮﻳا ﻧآ ﻪﻘﻄﻨﻣ ﻚﻳ ناﻮﻨﻋ ﻪﺑ ﻲﺘﺴﻳ

ﺪ ﻴﻳﺎﭘ ﻪﺟرد ﻚﻴﻣ ﺎﻳ و ﻦ

ﺖﻴﺗﺎﭙﻫ ﻪﺑ ﺖﺒﺴﻧ ﻲﻨﻤﻳا ﺮﻈﻧ زا ﻂﺳﻮﺘﻣ دﺮﻛ داﺪﻤﻠﻗA

) 15،16 (.

ﻢﻴﺴﻘﺗ ﺮﻈﻧ زا دﺰﻳ نﺎﺘﺳا ﻦﻴﺑ رد ﺖﺷاﺪﻬﺑ و شزﻮﻣآ ناﺰﻴﻣ يﺪﻨﺑ

ﺘﺳا نﺎ ﻲﻣ ﻂﻳاﺮﺷ ﻦﻳﺮﺘﻬﺑ رد ناﺮﻳا يﺎﻫ ﺪﺷﺎﺑ

) 17 ( ﻪﺑ ﻲﻣ ﺮﻈﻧ ﺪﺳر

نﺎﺘﺳا رد ﺎﻫ ﻳ ﻪﻛ نﺎﮔﺰﻣﺮﻫ و نﺎﺘﺴﻠﮔ ﺮﻴﻈﻧ ﻲ رد ﺖﻴﻧﻮﺼﻣ ناﺰﻴﻣ

لﺎﺳ 1390 ﻦﻴﻨﺳ داﺮﻓا يور ﺮﺑ 17

- 16 لﺎﺳ 8 / 86 % شراﺰﮔ

ﻦﻴﻳﺎﭘ يدﺎﺼﺘﻗا ﻲﻋﺎﻤﺘﺟا ﻂﻳاﺮﺷ ﺎﺑ ﻖﻃﺎﻨﻣ رد دﺰﻳ ﺖﺳا هﺪﺷ

(4)

،يدﺎﺼﺘﻗا ﻲﻋﺎﻤﺘﺟا ﻂﻳاﺮﺷ دﻮﺒﻬﺑ ﺎﺑ هﺪﻨﻳآ رد و هﺪﺷ بﻮﺴﺤﻣ نآ ﻲﻨﻤﻳا ﺖﻴﻌﺿو ﺎﻫ

ﻧ ﺰﻴ ﻲﻣ ﺮﻴﻴﻐﺗ ﺪﺑﺎﻳ ) 18،19 (.

ﺮﮕﻳد ﻪﻌﻟﺎﻄﻣ رد

هﺎﮕﺸﻧاد نﺎﻳﻮﺠﺸﻧاد يور ﺮﺑ لﺎﺳ رد ناﺮﻬﺗ

1390 ﻖﻃﺎﻨﻣ زا ﻪﻛ

ﺖﻴﺗﺎﭙﻫ يژﻮﻟوﺮﺳ ﺪﻧدﻮﺑ هﺪﻣآ رﻮﺸﻛ ﻒﻠﺘﺨﻣ ﻒﺼﻧ رد ﺎﻬﻨﺗ A

ﻦﺳ نﺎﻧاﻮﺟ ﺖﻴﻌﻤﺟ ﻒﺼﻧ ﺎﺒﻳﺮﻘﺗ ﻦﻳاﺮﺑﺎﻨﺑ دﻮﺑ ﺖﺒﺜﻣ نﺎﻳﻮﺠﺸﻧاد ﻲﻤﻧ رادرﻮﺧﺮﺑ ﺖﻴﻧﻮﺼﻣ زا هﺎﮕﺸﻧاد ﺪﻨﺷﺎﺑ

) 19،20 (.

ﺮﺑ هوﻼﻋ

ﻐﺗ ﻲﺋﺎﻴﺳآ يﺎﻫرﻮﺸﻛ و ﻪﻘﻄﻨﻣ يﺎﻫرﻮﺸﻛ رد ناﺮﻳا ﺖﻴﻌﺿو ﺮﻴﻴ

،يژﻮﻟﻮﻴﻣﺪﻴﭘا ﻲﻣ دﻮﻬﺸﻣ

ﺪﺷﺎﺑ ) 21،22،23 (

يﺮﮕﻳد ﻪﻌﻟﺎﻄﻣ رد

لﺎﺳ رد نارﺎﻜﻤﻫ و ﻲﻨﻴﺴﺣ 1395

يور ﺮﺑ 2494 ﻦﻴﺑ دﺮﻓ

ﻦﻴﻨﺳ 60 ﺎﺗ 68 ﺖﻴﺗﺎﭙﻫ يژﻮﻟوﺮﺳ ﻲﮕﻟﺎﺳ ﺪﻧدﺮﻛ ﻲﺳرﺮﺑ ار A

ﻪﻌﻟﺎﻄﻣ ﻦﻳا ﺞﻳﺎﺘﻧ ﺖﻴﺗﺎﭙﻫ ﺎﺑ طﺎﺒﺗرا رد ﻪﻛ داد نﺎﺸﻧ

ﺎﻣ رﻮﺸﻛA

ﺰﺟ و ﻣﺪﻧآ ﺎﺑ ﻖﻃﺎﻨﻣ ﻴ

ﺴ ﻴ ﻲﺘ ﻲﻣ ﻦﻴﻳﺎﭘ و ﻂﺳﻮﺘﻣ ﺪﺷﺎﺑ

) 24 ( ﺮﺑ ﻪﻛ

ﻪﻛ ﺪﻨﺘﺴﻫ ﻲﻘﻃﺎﻨﻣ وﺰﺟ ﻲﻧﺎﻬﺟ ﺖﺷاﺪﻬﺑ نﺎﻣزﺎﺳ ﻪﻴﺻﻮﺗ ﻖﺒﻃ ﺪﻨﻣزﺎﻴﻧ يﺮﺳاﺮﺳ نﻮﻴﺳﺎﻨﻴﺴﻛاو

Mass vaccination)

( ﺪﻨﺘﺴﻫ

) 25 ( . ﺖﻴﺗﺎﭙﻫ ﻪﻴﻠﻋ ﺖﻴﻧﻮﺼﻣ ناﺰﻴﻣ ﻲﺳرﺮﺑ يدﻮﺧ ﻪﺑ A

دﻮﺧ

ﻲﻤﻧ رد ﺪﻧاﻮﺗ ﻢﻴﻤﺼﺗ ﻦﺘﻓﺮﮔ

ياﺮﺑ مﺎﺠﻧا نﻮﻴﺳﺎﻨﻴﺴﻛاو ﻚﻳ رد

ﻪﻌﻣﺎﺟ ﺪﺷﺎﺑ ﺮﺛﻮﻣ اﺬﻟ

ﺖﻴﺗﺎﭙﻫ زا يدﺎﻳز دراﻮﻣ ﺶﻳاﺪﻴﭘ رد A

نارﺎﻤﻴﺑ درﻮﻣ ﻪﻌﻟﺎﻄﻣ ﺮﺿﺎﺣ ﻢﻫ و ﺖﻴﻧﻮﺼﻣ ﺖﻴﺿو ﺮﻴﻴﻐﺗ ﻦﻴﻨﭼ

ﺖﻴﺗﺎﭙﻫ ﻪﻴﻠﻋ زا A

ﺮﭙﻳﺎﻫ ﻪﻘﻄﻨﻣ ﻚﻳ ﻪﻘﻄﻨﻣ ﻪﺑ ﻚﻴﻣﺪﻧا

low

endimicity

ﺖﻴﺗﺎﭙﻫ ﻪﻴﻠﻋ نﻮﻴﺳﺎﻨﻴﺴﻛاو ﻪﺑ زﺎﻴﻧ ﺮﮕﻧﺎﻴﺑ ﻞﻗاﺪﺣA

ﻲﻣ ﺮﻄﺧ ضﺮﻌﻣ رد ﺖﻴﻌﻤﺟ رد ﺪﺷﺎﺑ

.

ﻪﺠﻴﺘﻧ يﺮﻴﮔ

ﺮﺿﺎﺣ لﺎﺣ ﻪﻌﻟﺎﻄﻣ رد 65

% رد دﺎﺣ ﺖﻴﺗﺎﭙﻫ دراﻮﻣ زا نارﺎﻤﻴﺑ

ﺖﻴﺗﺎﭙﻫ ار ﻲﻣ ﻞﻴﻜﺸﺗ A

داد . دﺎﺣ يرﺎﻤﻴﺑ دراﻮﻣ زا ﻲﻳﻻﺎﺑ ﺪﺻرد

ﺪﺒﻛ ﻪﺑ صﻮﺼﺧ رد ﻲﻧاﻮﺟ ﻦﻴﻨﺳ ﻞﻴﻟد ﻪﺑ

ﺖﻴﺗﺎﭙﻫ ﻲﻣ A

ﺪﺷﺎﺑ .

لﺎﺳ ﻪﺑ ﺖﺒﺴﻧ ﻪﻛ ﻞﺒﻗ ﻪﺑ ﺖﺒﺴﻧ ﻎﻟﺎﺑ داﺮﻓا ﻞﺒﻗ يﺎﻫ

و ﺮﺗﺪﻌﺘﺴﻣ

نﻮﻴﺳﺎﻨﻴﺴﻛاو ﻪﺑ زﺎﻴﻧ ﻪﺠﻴﺘﻧ رد ﻪﻴﻠﻋ

ﻫ ﭙ ﺖﻴﺗﺎ ﺪﻧرادA

.

سﺎﭙﺳ يراﺰﮔ

زا ﺻﺎﻨﻋ و ﻞﻣاﻮﻋ ﻲﻣﺎﻤﺗ رﺎﻜﻤﻫ و ﻞﻴﺧد ﺮ

رد ﻪﻛ ﻲﻧا

ﻊﻤﺟ هداد يروآ ﻪﺘﺷاد ﺶﻘﻧ ﺎﻫ

،ﺪﻧا ﻲﻣ ﺮﻜﺸﺗ دﻮﺷ

. ﻦﻤﺿ رد

دراﺪﻧ ﻲﻟﺎﻣ ﻲﻣﺎﺣ .

ﻊﻓﺎﻨﻣ رد ضرﺎﻌﺗ :

راﺪﻧ دﻮﺟو د

.

References:

1-Danni D, Grytdal S, Wasley A. Surveillance for Acute Viral Hepatitis- United States, 2007. MMWR Surveill Summ 2009; 58(3): 1-27.

2- Tazhibi M, Hajivand A, Tafti AD, Fallahzadah H.

The Efficacy of Hepatitis B Vaccine in Iranian Population: A Systematic Review and Meta- Analysis. J Educ Health Promot 2014; 3: 53.

3-Movahedi M , Haghdoost AA, Pournik O, Hajarizadeh B, Fallah MS. Temporal Variation of Health Indicator in Iran Comparing with other Eastern Mediterranean Region Countries in the

Last Two Decade. J Public Health (OXF) 2008; 30 (4): 499-504.

4- Jcobson KH, Wiersma ST. Hepatitis A Virus Seroprevalence by Age and World Region, 1990 and 2005. Vaccine 2010; 28(41): 6653-7.

5- World Health Organization, UNICEF. Progress on Sanitation and Drinking-Water 2013. Available at:

https://www.who.int/water_sanitation_health/publicatio ns/2013/jmp_report/en. Accessed Novmber 14, 2019.

6-Ayatollahi J, Hadinadoshan H. Evaluation of Anti- HAV Antibody in Secondary School Students of

(5)

دﺰﻳ ﻲﻗوﺪﺻ ﺪﻴﻬﺷ ﻲﻧﺎﻣرد ـ ﻲﺘﺷاﺪﻬﺑ تﺎﻣﺪﺧ و ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد ﻪﻠﺠﻣ

هرﺎﻤﺷ ، ﻢﺘﺸﻫ ، نﺎﺑآ 1398

Yazd City. Shahid Sadoughi Univ Med Sci 2001; 9(4):

87–90. [Persian]

7- Salehi M, Sane imoghadam E. Seroepidemiology of Hepatitis A in Population under 30 years old in Rural Area of Zabol. J Guilan Uni Med Sci 2001;

10(37 - 38): 26-9. [Persian]

8-Wasley A, Figre A, Bell BP. Hepatitis A in Era of Vaccination. Epidemiol Rev 2006; 28: 101-11.

9- Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L Hepatitis A: Epidemiology and Prevention in Developing Countries. World J Hepatol 2012; 4: 68-73.

10-Craig AS, Schaffener W.Prevention of Hepatitis A with the Hepatitis A Vaccine. N Engl J Med 2004;

350(5): 476-81.

11- Omana V, Guoliang Xia, Gilberto V, Harold S.

Diagnosis of Hepatitis A Virus Infection: a Molecular Approach. Clin Microbiol Rev 2006;

19(1): 63–79.

12-Ghorbani G, Ameli J, Ghandi HR.

Meningoencephalitis of Hepatitis A in Adult Man: A Case Report. Hepatitis Monthly 2008;

8(4): 313-6.

13- Moini M, Pahlavan-Sabagh MR, Dehghani SM.

Acute Liver Failure, Etiology and Outcome: An Experience in a Referral Liver Transplant Center.

Hepatitis Month 2017; 17(6): e14086.

14-Mehr AJ, Ardakani MJ, Hedayati M, Shahraz S, Mehr EJ, Zali MR. Age- Specific Seroprevalence of Hepatitis A Infection among Children Visited in Pediatric Hospital of Tehran Iran. Eur J Epidemiol 2004; 19(3): 275-8.

15- Ataei B, Javadi AA, Nokhadian Z, Kassaeian N, Shoaei P, Farajzadegan Z, et al. HAV in Isfahan

Province: A Population -Based Study. Trop Gastroentrol 2008; 29(3): 160-2.

16- Farajzadegan z, Ghaffari H, Kelishadi R, Jamshidi F, Nokhodian Z, Noori R, et al. Systematic Review and Meta-Analysis on the Age Specific Seroprevalence of Hepatitis a in Iran. J Res Med Sci 2014; 19(Suppl 1): S56-S63.

17- farzadfar F, danaei G, Namdaritabar H, Rajaratnam JK, Marcus JR, Khosravi A, et al. National and Subnational Mortality Effect of Metabolic Risk Factor in Iran: A Comparative Risk Assessment.

Popul Health Metr 2011; 9(1): 55-8.

18- Moradi A, Khodabakhshi B, Besharat S. Hepatitis A In Young Adults In The Golestan Province, Northeast Of Iran. J Glob Infect Dis 2010; 2(2): 198–199.

19-Salehi M, Izadi M, Bazzaz N, Jonaidi N, Ranjbar R, Khedmat H. Acute Viral Hepatitis in South-East of Iran: A Serological Analysis of 263 Case. Acta med Iran 2008; 46(5): 417-22.

20- Rabiee A ,Nikayeen S Hashemi SR, Mohaghegh M, Amini M, Rabiee R, Merat S. Seroprevalence of Hepatitis A among Students Enrolled in Tehran University of Medical Sciences during 2011. Middle East J Dig Dis 2013; 5(3): 137-40.

21- Hussain Z, Das BC , Husain SA , Murthy NS, Kar p. Increasing Trend of Acute Hepatitis A in North India: Need for Identification of High-Risk Population for Vaccination. J Gastroenterol Hepatol 2006; 21(4): 689-9.

22- Kim YJ, Lee HS. Increasing Incidence of Hepatitis A in Korean Adult. Intervirology 2010; 53(1): 10-4.

23-Sacy RG, Haddad M, Baasiri G, Khoriati A, Gerbaka BJ, Abu-Elyazeed R. Hepatitis a in Lebanon: A

(6)

Changing Epidemiological Pattern. AM J Trop med Hyg 2005; 7: 453-6.

24- Hoseini SG, Kelishadi R, Ataei B, Yaran M, Motlagh ME, Ardalan G, et al. Seroprevalence of Hepatitis A in Iranian Adolescents: Is the Time to

Introduce a Vaccine?.Epidemil infect 2016; 144(2):

291-6.

25- WHO position paper on hepatitis A vaccines – June 2012. Wkly Epidemiol Rec 2012; 87(28/29):

261–76 ..

(7)

Journal of Shahid Sadoughi University of Medical Sciences Vol 27 | NO 8 | Nov 2019

Vol 27| NO 8 | Nov 2019 Accepted: 15 Jun 2019

Assessment the Epidemiological Status of Patients with Acute Liver Hepatitis Referred to Shahid Sadoughi Hospital of Yazd From 2015 to 2018

Hassan Salmanroghani¹, Mahmud Baghbanian², Mohammad Hassan Rouzegari³, Mohsen Akhondi Meybodi⁴,MohammadKazem Amirbeigy⁵

Short communication

Introduction: Acute hepatitis has several causes. Transfusion of non-infected blood to the virus and avoidance of undesirable social contacts have reduced the prevalence of hepatitis B and C transmission. Improved socioeconomic status and access to healthy food and water have also reduced the prevalence of hepatitis E and A. The transition from Hyper Endimicity to Intermediate or Low Endimicity has increased the incidence of acute Hepatitis A especially in adults. The aim of this study was to determine the epidemiological status of patients with acute liver hepatitis referred to the Shahid Sadoughi Hospital of Yazd from 2015 to 2018

Methods: This cross-sectional study was performed on the patients referring to the gastrointestinal clinic of Shahid Sadoughi Hospital from 2015 to 2018. The sampling method was that after rule out chronic liver disease according to medical history and patient lab data, the patients imported to the category of acute liver disease. SPSS Inc, Chicago, IL; version 16 was used to determine the prevalence of each type of acute hepatitis.

Results: 23 patients were diagnosed with acute hepatitis, 14 were male and 9 were female. Hepatitis A was found in 15 patients, 2 patients had acute hepatitis B, 2 patients had autoimmune hepatitis, and 4 patients had other causes for hepatitis.

Conclusion: 65% of patients in this study had acute hepatitis A. Therefore, acute hepatitis A is one of the important factors in the development of acute liver disease study and is therefore one of the important factors in the development of acute liver disease.

Keywords: Acute viral hepatitis ,Hepatitis A, Endimicity

Citation: Salmanroghan S, Baghbanian M, Rouzegari MH, AkhondiMeybodi M, AmirbeigyMK. Assessment the epidemiological status of patients with acute liver hepatitis referred to Shahid Sadoughi Hospital of Yazd from 2015 to 2018. J Shahid Sadoughi Uni Med Sci 2019; 27(8): 1846-52.

1Gastroenterology Institute, Shahid Sadoughi University of Medical Sciences,Yazd, Iran

3Gastroenterology Iinstitute, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding author: Tel: 09131512000, email: [email protected]